Skorzewiak / Shutterstock.com
1 October 2024NewsEuropeLiz Hockley
UK judge ends J&J unit’s hopes of reviving Stelara patent
Janssen Biotech denied permission to appeal invalidation of ustekinumab patent | Samsung Bioepis convinced UK court to revoke patent in July.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
14 June 2023 Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.
Big Pharma
25 May 2023 Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.
Editor's picks
Editor's picks
Americas
14 June 2023 Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.
Big Pharma
25 May 2023 Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.
Americas
14 June 2023 Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.
Big Pharma
25 May 2023 Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.